Buckingham Research Upgrades Par Pharmaceutical (PRX) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St slips as climbing oil, yields amplify inflation fears
- Oil jumps 5%, then pares gains after Trump says no attack on Iran this month
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts PRX Hot Sheet
Price: $49.98 --0%
Rating Summary:
1 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 18 | New: 34
Rating Summary:
1 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 18 | New: 34
Join SI Premium – FREE
Buckingham Research upgraded Par Pharmaceutical (NYSE: PRX)from Neutral to Buy with a new price target of $45.00.
For an analyst ratings summary and ratings history on Par Pharmaceutical click here. For more ratings news on Par Pharmaceutical click here.
Shares of Par Pharmaceutical closed at $34.01 yesterday.
For an analyst ratings summary and ratings history on Par Pharmaceutical click here. For more ratings news on Par Pharmaceutical click here.
Shares of Par Pharmaceutical closed at $34.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Melius Upgrades CAVA Group Inc (CAVA) to Buy, 'Paying Less for More Proof'
- Loop Capital Upgrades PROG Holdings (PRG) to Buy
- Deutsche Bank Upgrades Chime Financial (CHYM) to Buy, 'Gaining Confidence in the Growth Algorithm'
Create E-mail Alert Related Categories
UpgradesRelated Entities
Buckingham ResearchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
